The prevalence of type 2 diabetes is rising rapidly, devastating the lives of millions of Americans. Extensive studies demonstrate that inflammation induces insulin resistance, contributing to type 2 diabetes. Blood glucose levels are determined by a balance between insulin and counterregulatory hormones (e.g. glucagon and catecholamines);however, potential effects of inflammation on glucagon and catecholamine sensitivity have not been studied. Furthermore, signaling pathways that mediate inflammation regulation of hepatic steatosis are poorly defined. Our preliminary study suggests that NF- B-inducing kinase (NIK) is not only a novel regulator of glucagon/catecholamine sensitivity but also defines new pathways that regulate lipogenesis and fatty acid oxidation. NIK is a ubiquitously-expressed Ser/Thr kinase activated by a subset of cytokines, and is required for the activation of the noncanonical NF- B2, but not the canonical IKK /NF- B1, pathway. NIK regulates T cell, B cell, and osteoclast development, but its role in metabolism has not been studied. We observed that NIK enhanced the ability of glucagon to increase cAMP levels and hepatic glucose production (HGP) but did not directly regulate insulin signaling. NIK phosphorylated CREB and increased its stability. CREB mediates glucagon/catecholamine stimulation of HGP and also promotes lipogenesis. NIK null mice developed glucagon resistance and were protected from dietary hyperglycemia and hepatic steatosis. Deletion of NIK decreased lipogenesis and increased oxidation in hepatocytes. Hepatic NIK was aberrantly activated in obesity;CREB and activated NF- B2 levels were increased in the livers of mice with obesity and humans with alcoholic fatty liver disease or hepatitis C. Obesity was associated with an increase in Cdc37 (an Hsp90 cochaperone) that bound to NIK. We propose that hepatic NIK is abnormally activated in obesity due to dysregulation of NIK chaperones (Cdc37/Hsp90), NIK E3 ligases (cIAP1/2), and hepatocyte-Kupffer cell crosstalk. Obesity-associated NIK overactivation increases glucagon/catecholamine sensitivity, HGP, and lipogenesis through CREB, and decreases oxidation through NF- B2.
In Aim 1, we will determine whether hepatic NIK cell-autonomously promotes glucagon/catecholamine sensitivity by increasing CREB stability and decreasing cAMP (a second messenger for glucagon and catecholamines) degradation, and whether hepatocyte-specific deletion of NIK protects against type 2 diabetes.
In Aim 2, we will determine whether hepatic NIK directly promotes lipogenesis via CREB and suppresses -oxidation via NF- B2, and whether hepatocyte-specific deletion of NIK protects against hepatic steatosis.
In Aim 3, we will determine whether obesity is associated with dysregulation of the Cdc37/Hsp90 chaperone machinery, cIAP1/2 E3 ligase activity, and hepatocyte-Kupffer cell crosstalk, and whether these three factors drive NIK hyperactivity. The outcome is expected to lead to new therapies for hepatic steatosis and type 2 diabetes by targeting the NIK pathways.

Public Health Relevance

The prevalence of type 2 diabetes and fatty liver diseases continues to rise rapidly, devastating millions of American life. Unfortunately, our ability to tret these diseases is limited because their molecular mechanisms remain largely unknown. In the proposed study, we will determine how inflammation and cellular stress promote type 2 diabetes and fatty liver diseases, focusing on a protein kinase called NIK. The outcome of this project is expected to lead to new treatments of these two common diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK091591-02
Application #
8518315
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Abraham, Kristin M
Project Start
2012-08-01
Project End
2016-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$367,641
Indirect Cost
$131,216
Name
University of Michigan Ann Arbor
Department
Physiology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Chen, Zheng; Morris, David L; Jiang, Lin et al. (2014) SH2B1 in ?-cells promotes insulin expression and glucose metabolism in mice. Mol Endocrinol 28:696-705
Rui, Liangyou (2014) SH2B1 regulation of energy balance, body weight, and glucose metabolism. World J Diabetes 5:511-26
Chen, Zheng; Morris, David L; Jiang, Lin et al. (2014) SH2B1 in ?-cells regulates glucose metabolism by promoting ?-cell survival and islet expansion. Diabetes 63:585-95
Shen, Hong; Sheng, Liang; Chen, Zheng et al. (2014) Mouse hepatocyte overexpression of NF-?B-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis. Hepatology 60:2065-76
Rui, Liangyou (2014) Energy metabolism in the liver. Compr Physiol 4:177-97
Hu, Jun; Jiang, Lin; Low, Malcolm J et al. (2014) Glucose rapidly induces different forms of excitatory synaptic plasticity in hypothalamic POMC neurons. PLoS One 9:e105080
Sheng, Liang; Jiang, Bijie; Rui, Liangyou (2013) Intracellular lipid content is a key intrinsic determinant for hepatocyte viability and metabolic and inflammatory states in mice. Am J Physiol Endocrinol Metab 305:E1115-23
Rui, Liangyou (2013) Brain regulation of energy balance and body weight. Rev Endocr Metab Disord 14:387-407